Abstract
Helicobacter pylori infection is associated with various gastroduodenal pathologies ranging from gastritis and peptic ulcer disease to gastric cancer. The most current guidelines for the diagnosis, indications for therapy and treatment strategies of H. pylori are outlined in the third Maastricht Consensus conference which was convened by the European Helicobacter Study Group (EHSG)1. The diagnosis of H. pylori infection is established using invasive or non-invasive methods2–6. Non-invasive tests are the urea-breath test, stool-antigen tests and serological kits with a high accuracy7. Invasive tests include endoscopy with gaining of gastric biopsies for urea test (HUT®, Helicobacter urease test) or histology (e.g. Whartin Starry silver staining). Eradication of H. pylori infection is recommended in patients with gastroduodenal pathologies such as peptic ulcer disease and low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma, atrophic gastritis, first-degree relatives of gastric cancer patients, unexplained iron deficiency anaemia and chronic idiopathic thrombocytopenic purpura8–10. Triple therapy using a proton pump inhibitor (PPI) with amoxicillin and clarithromycin or metronidazole given twice daily remains the recommended first-choice therapy1. Bismuth containing quadruple therapy is also a first-choice treatment option. Rescue therapy should be based on antimicrobial susceptibility1. The risk of untreated H. pylori infection appears to be highest in patients who require long-term treatment with non-steroidal anti-inflammatory agents11–13.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Malfertheiner P, Megraud F, O’Morain C et al. Current concepts in the management of Helicobacter pylori infection — the Maastricht III Consensus Report. Gut. 2007, Jan 17; Epub ahead of print.
Gisbert JP, Pajares JM. Review article: C-urea breath test in the diagnosis of Helicobacter pylori infection — a critical review. Aliment Pharmacol Ther. 2004;20:100–17.
Perri F, Manes G, Neri M et al. Helicobacter pylori antigen stool test and 13C-urea breath test in patients after eradication treatments. Am J Gastroenterol 2002;97:2756–62.
Vakil N, Rhew D, Soll A et al. The cost-effectiveness of diagnostic testing strategies for Helicobacter pylori. Am J Gastroenterol. 2000;95:1691–8.
Loy CT, Irwig LM, Katelaris PH et al. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol 1996;91:1138–44.
Vaira D, Holton J, Menegatti M et al. Review article: Invasive and non-invasive tests for Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14(Suppl. 3):13–22.
Dzierzanowska-Fangrat K, Lehours P, Megraud F et al. Diagnosis of Helicobacter pylori infection. Helicobacter. 2006;11(Suppl. 1):6–13.
Moayyedi P, Deeks J, Talley NJ et al. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003;98:2621–6.
Du Bois S, Kearney DJ. Iron-deficiency anemia and Helicobacter pylori infection: a review of the evidence. Am J Gastroenterol 2005;100:453–9.
Gasbarrini A, Franceschi F, Tartaglione R et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori Lancet. 1998;352:878.
Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and nonsteroidal antiinflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14–22.
Hawkey CJ, Tulassay Z, Szczepanski L et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet. 1998;352:1016–21.
Chan FK, To KF, Wu JC et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal antiinflammatory drugs: a randomised trial. Lancet. 2002;359:9–13.
Fischbach W, Dragosics B, Kolve-Goebeler ME et al. Primary gastric B-cell lymphoma: results of a prospective multicenter study. German-Austrian Gastrointestinal Lymphoma Study Group. Gastroenterology. 2000;119:1191–202.
Ye W, Held M, Lagergren J et al. H. pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst. 2004;96:388–96.
Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001;49:347–53.
Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.
Malfertheiner P, Sipponen P, Naumann M et al. H. pylori Gastric Cancer Task Force. H. pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol. 2005;100:2100–15.
Lehours P, Ruskone-Fourmestraux A, Lavergne A et al. Which test to use to detect Helicobacter pylori infection in patients with low-grade gastric mucosa associated lymphoid tissue lymphoma? Am J Gastroenterol. 2003;98:291–5.
Megraud F. Update on therapeutic options for Helicobacter pylori-related diseases. Curr Infect Dis Rep. 2005;7:115–20.
Chey WD, Fendrick AM. Noninvasive Helicobacter pylori testing for the ‘test and-treat’ strategy: a decision analysis to assess the effect of past infection on test choice. Arch Intern Med. 2001;161:2129–32.
Moayyedi P, Soo S, Deeks J et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. Br Med J. 2000;321:659–64.
Malfertheiner P, Fry LC, Mönkemüller K. Can gastric cancer be prevented by Helicobacter pylori eradication? Best Pract Res Clin Gastroenterol. 2006;20:709–19.
Nardone G, Rocco A, Malfertheiner P. Review article: Helicobacter pylori and molecular events in precancerous gastric lesions. Aliment Pharmacol Ther. 2004;20:261–70.
Wong BC, Lam SK et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. J Am Med Assoc. 2004;291:187–94.
Zhou LY, Lin SR, Ding SG et al. The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chin J Dig Dis. 2005;6:114–15.
Uemura N, Mukai T, Okamoto S et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev. 1997;6:639–42.
Ito M, Haruma K et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther. 2002;16:1449–56.
Mera R, Fontham ET, Bravo LE et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut. 2005;54:1536–40.
Take S, Mizuno M, Ishiki K et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. Gastroenterol. 2007;42(Suppl. 17):21–7.
Tepes B, Kavcic B, Zaletel LK et al. Two-to four-year histological follow-up of gastric mucosa after Helicobacter pylori eradication. J Pathol. 1999;188:24–9.
Sung JJ, Lin SR, Ching JY et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology. 2000;119:7–14.
Rocco A, Suriani R, Cardesi E, Venturini I, Mazzucco D, Nardone G. Gastric atrophy and intestinal metaplasia changes 8 years after Helicobacter pylori eradication. A blind, randomized study. Minerva Gastroenterol Dietol. 2002;48:175–8.
Zhou L, Sung JJ, Lin S et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chin Med J. 2003;116:11–14.
Lu B, Chen MT, Fan YH, Liu Y, Meng LN. Effects of Helicobacter pylori eradication on atrophic gastritis and intestinal metaplasia: a 3-year follow-up study. World J Gastroenterol. 2005;11:6518–20.
Salih BA, Abasiyanik MF, Saribasak H, Huten O, Sander E. A follow-up study on the effect of Helicobacter pylori eradication on the severity of gastric histology. Dig Dis Sci. 2005;50:1517–22.
Arkkila PE, Seppala K, Farkkila MA, Veijola L, Sipponen P. Helicobacter pylori eradication in the healing of atrophic gastritis: a one-year prospective study. Scand J Gastroenterol. 2006;41:782–90.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer and Falk Foundation e.V.
About this paper
Cite this paper
Mönkemüller, K., Neumann, H., Fry, L.C., Malfertheiner, P. (2008). Helicobacter pylori infection: diagnosis, treatment and risks of untreated infection. In: Ferkolj, I., Gangl, A., Galle, P.R., Vucelic, B. (eds) Pathogenesis and Clinical Practice in Gastroenterology. Falk Symposium, vol 160. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-8767-7_5
Download citation
DOI: https://doi.org/10.1007/978-1-4020-8767-7_5
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-8766-0
Online ISBN: 978-1-4020-8767-7
eBook Packages: MedicineMedicine (R0)